PTO/AIA/82A (07-12)
`Approved for use through 11130/2014. OMB 0651-0035
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
`
`TRANSMITTAL FOR POWER OF ATTORNEY TO ONE OR MORE
`REGISTERED PRACTITIONERS
`
`NOTE: This form is to be submitted with the Power of Attorney by Applicant form (PTO/AIA/828 or equivalent) to identify the
`application to which the Power of Attorney is directed, in accordance with 37 CFR 1.5. If the Power of Attorney by Applicant form
`is not accompanied by this transmittal form or an equivalent, the Power of Attorney will not be recognized in the application.
`
`Application Number
`
`Filing Date
`
`First Named Inventor
`
`Curt Wolfgang et al.
`
`Title
`
`Art Unit
`
`Examiner Name
`
`METHODS FOR THE ADMINISTRATION OF ILOPERIDONE
`
`Attorney Docket Number VAND-0002-US-CON2
`
`Signature
`
`SIGNATURE of Applicant or Patent Practitioner
`/Jayme M. Torelli/
`Jayme M. Torelli
`Name
`Registration Number 62,735
`
`Date
`
`01/08/2014
`Telephone 51 8-449-0044
`
`NOTE: This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4(d) for signature requirements and certifications.
`
`D *Total of
`
`forms are submitted.
`
`This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and
`by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes
`to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any
`comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer,
`U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED
`FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
`
`If you need assistance in completing the form, ca/11-800-PT0-9199 and select option 2.
`
`Roxane Labs., Inc.
`Exhibit 1002
`Page 001
`
`

`
`PTO/A!N82B(07 · ·12)
`Approved for use through ii/3012014. OMB -:1651-0035
`U.S. Patent end Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under lhe Papen.vcrk Reduction Act of ·1995, no persons are required lc respond to a collection of information W'!ess it displays a valid OMS controi number.
`POWER OF ATTORNEY BY APPL~CANT
`
`[
`
`l
`
`i hereby revoke all previous powers of attorney given in the application identified in the attached transmittal letter.
`~ l hereby appoint Practitioner(s) associated with the foiiowing Customer Number as my/our attomey{s) or agent(s), and to
`transact all business in the United States Patent and Trademarl~ Office connected therewith for the application referenced
`in the attached transmittal letter (form PTO!AIAI82A or equivalent):
`,.2.35.5a············---~
`
`[
`
`OR
`L~~~~~~~~------------------------------------------------
`i I hereby appoint Practitloner(s) named below as my/our attorney(s} or agent(s), and to transact all business in the
`-' United States Patent and Trademark Office connected therewith for the application referenced in the attached
`transmittal letter {form PTO/A!AI82A or equivalent):
`
`Name
`
`Registration
`Number
`
`i
`I
`
`Name
`
`Registration
`Number
`
`Please recognize or change the correspondence address for the application identified in the attached
`transmittal letter to:
`[IJ The address associated wit11 the above-mentioned Customer Number.
`r ........................... ~ ..
`OR
`
`[ ] The address associated wilh Customer Number: L
`---·0·-··Fl!:;:~·;;·~---------------:r··-------------------------------------------------------------------------------------------------····-··--·····-···- -
`lndlvid~al Name
`!
`Address
`I
`
`OR
`
`1
`
`-----
`
`City
`Country
`Telephone
`I am the Applicant:
`[ ] lnventor or Joint lnventor
`
`I
`I
`
`I
`
`-------------------------------------------------------------------
`
`I Zip I
`
`State
`
`I Ema!i
`
`-----------------------------
`!
`
`<
`
`--········----~-----··
`
`! September 21, 2012
`! Date
`I Telephone 1-202~734-;;;-., ~---------------··-··-·-·
`
`0Legal Representative of a Deceased or Legally incapacitated inventor
`[ljAsslgnee or Person to Whom the Inventor is Under an Obligation to Assign
`OPerson Who Otherwise Shows Sufficient Proprietary Interest (e.g., a petition under 37 CFR 1 .46(b)(2) was
`granted in the application or is concurrently being filed with this document)
`\\. SIGNATURE of Applicant for Patent
`i\
`i ~\j""'-...\~
`Signature
`eropoulos
`Name
`1 Mihae~'H'.
`Title and Com anv CEO, lfanda Pharmaceutical Inc,
`NQI!;: Signature- This form must be signed by the applicant in accordance with 37 CFR ·t33. See 37 CFR 1.4 for signature requirements and
`certifications. Submit multiple forms for more than one signature, see below •.
`0 'Total of
`This collection of infe<mai1on is reqtlired b>' ~7 CFR 1.3·1, '1.32 and 1.33. The inrormation is requ•rect to obtain or retain a benefit by the ~'..iblic which is to !iie (and by !he
`USPTO to process) an appiicetion. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR i.11 ar.d 1.14. This coi!ec!ion is es!imat.tOd lo !a:ke 3 minutes to complele.
`including g-athering, p-reparil1g, and submitting the completed application form!<) the USPTO. Time wlil vat1 depending upon the individual case. Any comments or..
`the amount of time you ;eqwlra lo et~mpieie this form and/or sugg.!<StiCn$ fa( redudng this b~crden, should be sen1 ic \he ChiE>f !niormation Officer, U.S. Patent and
`Tr;ao:Jemarl< Office, U.S Oepartmerlt of Commerce, P.O. Box 1450, Nexandria, VA 22313-1450. 00 NOT SEND FEES OR COMPLETED FORMS TO THIS
`ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA .22313•1450.
`
`forms are submitted.
`
`lfyou need assistance in completing the form, call 1--800-PT0-9199 and select option 2.
`
`Roxane Labs., Inc.
`Exhibit 1002
`Page 002
`
`

`
`Privacy Act Statement
`
`The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection
`with your submission of the attached form related to a patent application or patent. Accordingly,
`pursuant to the requirements of the Act, please be advised that: (1) the general authority for the
`collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary;
`and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark
`Office is to process and/or examine your submission related to a patent application or patent. If you do
`not furnish the requested information, the U.S. Patent and Trademark Office may not be able to
`process and/or examine your submission, which may result in termination of proceedings or
`abandonment of the application or expiration of the patent.
`
`The information provided by you in this form will be subject to the following routine uses:
`
`1. The information on this form will be treated confidentially to the extent allowed under the
`Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from
`this system of records may be disclosed to the Department of Justice to determine whether
`disclosure of these records is required by the Freedom of Information Act.
`2. A record from this system of records may be disclosed, as a routine use, in the course of
`presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to
`opposing counsel in the course of settlement negotiations.
`3. A record in this system of records may be disclosed, as a routine use, to a Member of
`Congress submitting a request involving an individual, to whom the record pertains, when the
`individual has requested assistance from the Member with respect to the subject matter of the
`record.
`4. A record in this system of records may be disclosed, as a routine use, to a contractor of the
`Agency having need for the information in order to perform a contract. Recipients of
`information shall be required to comply with the requirements of the Privacy Act of 1974, as
`amended, pursuant to 5 U.S.C. 552a(m).
`5. A record related to an International Application filed under the Patent Cooperation Treaty in
`this system of records may be disclosed, as a routine use, to the International Bureau of the
`World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
`6. A record in this system of records may be disclosed, as a routine use, to another federal
`agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to
`the Atomic Energy Act (42 U.S.C. 218(c)).
`7. A record from this system of records may be disclosed, as a routine use, to the Administrator,
`General Services, or his/her designee, during an inspection of records conducted by GSA as
`part of that agency's responsibility to recommend improvements in records management
`practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall
`be made in accordance with the GSA regulations governing inspection of records for this
`purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not
`be used to make determinations about individuals.
`8. A record from this system of records may be disclosed, as a routine use, to the public after
`either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent
`pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37
`CFR 1.14, as a routine use, to the public if the record was filed in an application which
`became abandoned or in which the proceedings were terminated and which application is
`referenced by either a published application, an application open to public inspection or an
`issued patent.
`9. A record from this system of records may be disclosed, as a routine use, to a Federal, State,
`or local law enforcement agency, if the USPTO becomes aware of a violation or potential
`violation of law or regulation.
`
`Roxane Labs., Inc.
`Exhibit 1002
`Page 003
`
`

`
`Doc Code: TRACK1.REQ
`Document Description: Trac!{One Request
`
`PTQ/I\lN424 (03-13}
`
`CERTIFICATION AND REQUEST FOR PRIORITIZED EXAMINATION
`UNDER 37 CFR 1.102(e) (Page 1 of1)
`
`Curt Wolfgang et a!.
`
`I ~~~;~~trl5k'">na! Application Number (if I
`
`METHODS FOR THE ADMINISTRATION OF ILOPERIDONE
`
`First Named
`inventor:
`
`Tille of
`invention:
`
`APPLICANT HEREBY CERTIFIES THE FOLLOWING AND REQUESTS PRIORITIZED EXAMINATION FOR
`THE ABOVE-IDENTIFIED APPLICATION.
`
`i. The processing fee set forth in 37 CFR 1. i 7(i)(1 ), the prioritized examination fee set forth in
`37 CFR 1.17(c), and if not already paid, the publication fee set forth in 3·7 CFR 1.18(d) have
`been filed with the request The basic filing fee, search fee, examination fee, and any required
`excess claims and application size fees are filed with the request or have been already been
`paid.
`
`2. The application contains or is amended to contain no more than four independent claims and no
`more than thirty total claims, and no multiple dependent claims.
`
`L
`
`I.
`
`3. The applicable box is checked below:
`2J Original Application (Track One)~ Prioritized Examination under§ 'L102(eH1)
`(a) The application is an original nonprovisional utility application filed under :--15 U.S.C. 111(a).
`This certification and request is being filed with the utility application via EFS~Web.
`~--OR-~-
`(b) The application is an original nonprovisiona! plant application filed under 35 U.S.C. 111 (a).
`This ce1iification and request is being filed with the plant application in paper.
`
`li. The executed inventor's oath or declaration is filed with the application. (37 CFR 1.63 and ·1.64)
`fi Request for Continued Examination~ Prioritized Examination under§ 1. 102(e}(2)
`
`IL
`
`.A request for continued examination has been filed with, or prior to, this form.
`i.
`If the application is a uti!ity application, this certification and request is being filed via EFS-Web.
`iL
`iii. The application is an original nonprovisional utility application filed under 35 U.S.C. 111(a), or is
`a national stage entry under 35 U.S.C. 371.
`iv. This certification and request is being fiied prior to the mailing of a first Office action responsive
`to the request for continued examination.
`v. No prior request for continued examination has been granted prioritized examination status
`under 37 CFR ·J.102(e){2).
`
`!!..Q.(~: T!1is forrn rr:ust be signed h? accordance ~~t:'ifh 37 CFR 1.33. SE:t.) 37 CFI=?. 1.4(d) for signature requirements and certifh---:c:tions.
`Subrnit multiple forms if rnore than one signature is requireci. 'k
`
`D 'Total of ___ forms me subrflit!ed
`
`Roxane Labs., Inc.
`Exhibit 1002
`Page 004
`
`

`
`Privacy Act Statement
`
`The Privacy Act of 1974 (P.L 93-579) requires that you be given certain inforrnation in connection with your
`submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of
`the Act, please be advised that (1) the genera! authority for the co!!edion of this infom1ation is 35 U.S.C. 2(b)(2); (2}
`furnishing ofthe information soHciied is voluntary; and (3) the principal purpose for which the information is used by the
`U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or
`patent If you do not furnish the requested information, the U.S. Patenl and Trademark Office may not be able to
`process and/or examine your submission, which may result in termination of proceedings or abandonment of the
`application or expiration of the p;:~tent
`
`The information provided by you in this form wi!! be subject to the following routine uses:
`
`1. The information on this form wi!l be treated confidentiaily to the extent allowed under the Freedom of
`information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may
`be disclosed to the Department of Justice lo determine whether disclosure of these records is required by the
`Freedom of Information Act.
`2. A record from this system of records may be disclosed, as a routine use, ln the course o·f presenting evidence
`to a court, magisirate, or administrative tribuna!, including disclosures to opposing counsel in the wurse of
`settlement negotiations.
`3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a
`request lnvo!ving an individual, to whom the record pertains, when the individual has requested assistance from
`the fvlember with respect to the subject matter of the record.
`4. A record in this system of records rnay be disclosed, as a routine use, to a contractor of the Agency having
`need for the information in order to perform a contract. Recipients of info(;nation shall be required to comply
`with the requirements of the Privacy f.\ct of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
`5. A record related to an international Application l1led under ihe Patent Cooperation Treaty in t!-tis systero of
`records may be disclosed, as a routine use, to the International Bure;:tu of the World lntei!ectual Property
`Oq~anization, pursuant to the Patent Cooperation Treaty.
`6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes
`of National Security review (35 U.S.C. "181) and for review pursuant to the Atomic Energy Act (42 U.S.C.
`2'l8(c)).
`7. A record from this svstem of records rnav be disclosed. as a routine use. to the Administrator, Genera!
`Services, or his/her-designee, durinfl an 'inspecllon of r~cords conducted by GSA as part of that agency's
`responsibility to recommend improvements in records management prac:ticE!s and programs, under authority of
`44 U.S C. 2904 and 2906. Such disclosure shall be made in accordance with the GS.~ refJU!ations governing
`inspection of rewrds for this purpose, and any other relevant (i.e., GS.A or Commerce) directive. Such
`disclosure shaH not be used to make determinations about individuals.
`8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of
`the application pursuant to 35 U.S.C. 122{b) or issuance of a patent pursuant to ~~5 U.S.C. 151. Further, a
`record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record
`was filed in an application which became abandoned or in which the proceedings were terminated and which
`application is referenced by either a published application, an applic..ation open to pub!ic inspection or an issued
`patent.
`9. A record from this system of records may be disclosed, as a routinE! use, to a Federal, State, or local law
`enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.
`
`Pagc2
`
`Roxane Labs., Inc.
`Exhibit 1002
`Page 005
`
`

`
`PTO/AIN14 (03-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`VAND-0002-US-CON2
`
`Application Number
`
`Title of Invention
`
`I METHODS FOR THE ADMINISTRATION OF ILOPERIDONE
`
`The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the
`bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76.
`This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the
`document may be printed and included in a paper filed application.
`
`Secrecy Order 37 CFR 5.2
`Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to
`D 37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)
`
`Inventor Information:
`
`1
`Inventor
`Legal Name
`
`I Remove I
`
`Prefix Given Name
`
`Middle Name
`
`Family Name
`
`Suffix
`
`Wolfgang
`Curt
`0 Non US Residency 0 Active US Military Service
`Residence Information (Select One) (!) US Residency
`I State/Province I MD
`I Country of Residence i I US
`City Germantown
`
`Mailing Address of Inventor:
`
`Address 1
`Address 2
`
`City
`
`I Washington
`Postal Code
`
`2
`Inventor
`Legal Name
`
`2200 Pennsylvania Avenue
`
`1 2oo37
`
`I State/Province
`I Country i
`1 us
`
`I DC
`
`I Remove I
`
`Prefix Given Name
`
`Middle Name
`
`Family Name
`
`Suffix
`
`Polymeropoulos
`Mihael
`0 Non US Residency O Active US Military Service
`Residence Information (Select One) (!) US Residency
`I State/Province I MD
`I Country of Residence i I US
`Potomac
`City
`
`Mailing Address of Inventor:
`
`Address 1
`
`2200 Pennsylvania Avenue
`
`Address 2
`
`City
`
`I Washington
`Postal Code
`
`I State/Province
`I Country i
`1 us
`1 2oo37
`All Inventors Must Be Listed - Additional Inventor Information blocks may be
`generated within this form by selecting the Add button.
`
`I DC
`
`I
`
`Add
`
`I
`
`Correspondence Information:
`Enter either Customer Number or complete the Correspondence Information section below.
`For further information see 37 CFR 1.33(a).
`
`EFS Web 2.2.6
`
`Roxane Labs., Inc.
`Exhibit 1002
`Page 006
`
`

`
`PTO/AIN14 (03-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`VAND-0002-US-CON2
`
`Application Number
`
`Title of Invention METHODS FOR THE ADMINISTRATION OF ILOPERIDONE
`
`D An Address is being provided for the correspondence Information of this application.
`Customer Number
`23550
`
`Email Address
`
`Application Information:
`
`I I Add Email I
`
`!Remove Email I
`
`Title of the Invention
`
`Attorney Docket Number VAND-0002-US-CON2
`
`METHODS FOR THE ADMINISTRATION OF ILOPERIDONE
`I Small Entity Status Claimed D
`
`Application Type
`
`Nonprovisional
`
`Subject Matter
`
`Utility
`
`I
`
`I Suggested Figure for Publication (if any) I
`
`Total Number of Drawing Sheets (if any)
`Publication Information:
`D Request Early Publication (Fee required at time of Request 37 CFR 1.219)
`Request Not to Publish. I hereby request that the attached application not be published under
`D 35 U.S.C. 122(b) and certify that the invention disclosed in the attached application has not and will not be the
`subject of an application filed in another country, or under a multilateral international agreement, that requires
`publication at eighteen months after filing.
`
`Representative Information:
`
`Representative information should be provided for all practitioners having a power of attorney in the application. Providing
`this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32).
`Either enter Customer Number or complete the Representative Name section below. If both sections are completed the customer
`Number will be used for the Representative Information during processing.
`
`Please Select One:
`
`Customer Number
`
`® Customer Number
`23550
`
`I 0 US Patent Practitioner IO Limited Recognition (37 CFR 11.9)
`
`Prior Application Status Pending
`
`Domestic Benefit/National Stage Information:
`This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, or 365(c) or indicate
`National Stage entry from a PCT application. Providing this information in the application data sheet constitutes the
`specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78.
`I Remove I
`Filing Date (YYYY-MM-DD)
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`Prior Application Status Patented
`
`Continuation of
`
`14060978
`
`2013-10-23
`I Remove I
`
`EFS Web 2.2.6
`
`Roxane Labs., Inc.
`Exhibit 1002
`Page 007
`
`

`
`PTO/AIN14 (03-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`VAND-0002-US-CON2
`
`Application Number
`
`Title of Invention METHODS FOR THE ADMINISTRATION OF ILOPERIDONE
`
`Application
`Number
`
`Continuity Type
`
`Prior Application
`Number
`
`Filing Date
`(YYYY-MM-DD)
`
`Patent Number
`
`Issue Date
`(YYYY-MM-DD)
`
`14060978
`
`Continuation of
`
`11/576178
`
`2007-03-28
`
`Prior Application Status Expired
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`11/576178
`
`a 371 of international
`
`PCT/US2005/035526
`
`Prior Application Status Expired
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`PCT/US2005/035526
`
`non provisional of
`
`60614798
`
`Additional Domestic Benefit/National Stage Data may be generated within this form
`by selecting the Add button.
`
`Foreign Priority Information:
`
`8586610
`
`2013-11-19
`I Remove I
`Filing Date (YYYY-MM-DD)
`
`2005-09-30
`I Remove I
`Filing Date (YYYY-MM-DD)
`
`2004-09-30
`I Add
`
`I
`
`This section allows for the applicant to claim priority to a foreign application. Providing this information in the application data sheet
`constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55(d). When priority is claimed to a foreign application
`that is eligible for retrieval under the priority document exchange program (POX) ithe information will be used by the Office to
`automatically attempt retrieval pursuant to 37 CFR 1.55(h)(1) and (2). Under the POX program, applicant bears the ultimate
`responsibility for ensuring that a copy of the foreign application is received by the Office from the participating foreign intellectual
`property office, or a certified copy of the foreign priority application is filed, within the lime period specified in 37 CFR 1.55(g)(1 ).
`
`Application Number
`
`Country i
`
`Filing Date (YYYY-MM-DD)
`
`Access Codei (if applicable)
`
`1 Remove 1
`
`Additional Foreign Priority Data may be generated within this form by selecting the
`Add button.
`
`I Add I
`
`Statement under 37 CFR 1.55 or 1.78 for AlA (First Inventor to File) Transition
`Applications
`
`This application (1) claims priority to or the benefit of an application filed before March 16, 2013 and (2) also
`D contains, or contained at any time, a claim to a claimed invention that has an effective filing date on or after March
`16, 2013.
`
`Authorization to Permit Access:
`
`~ Authorization to Permit Access to the Instant Application by the Participating Offices
`
`EFS Web 2.2.6
`
`Roxane Labs., Inc.
`Exhibit 1002
`Page 008
`
`

`
`PTO/AIN14 (03-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`VAND-0002-US-CON2
`
`Application Number
`
`Title of Invention METHODS FOR THE ADMINISTRATION OF ILOPERIDONE
`
`If checked, the undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO),
`the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the World Intellectual Property Office (WI PO),
`and any other intellectual property offices in which a foreign application claiming priority to the instant patent application
`is filed access to the instant patent application. See 37 CFR 1.14(c) and (h). This box should not be checked if the applicant
`does not wish the EPO, JPO, KIPO, WI PO, or other intellectual property office in which a foreign application claiming priority
`to the instant patent application is filed to have access to the instant patent application.
`
`In accordance with 37 CFR 1.14(h)(3), access will be provided to a copy of the instant patent application with respect
`to: 1) the instant patent application-as-filed; 2) any foreign application to which the instant patent application
`claims priority under 35 U.S.C. 119(a)-(d) if a copy of the foreign application that satisfies the certified copy requirement of
`37 CFR 1.55 has been filed in the instant patent application; and 3) any U.S. application-as-filed from which benefit is
`sought in the instant patent application.
`
`In accordance with 37 CFR 1.14(c), access may be provided to information concerning the date of filing this Authorization.
`
`Applicant Information:
`
`Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR
`to have an assignment recorded by the Office.
`
`Applicant 1
`If the applicant is the inventor (or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed.
`The information to be provided in this section is the name and address of the legal representative who is the applicant under 37 CFR
`1.43; or the name and address of the assignee, person to whom the inventor is under an obligation to assign the invention, or person
`who otherwise shows sufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46. If the applicant is an
`applicant under 37 CFR 1.46 (assignee, person to whom the inventor is obligated to assign, or person who otherwise shows sufficient
`proprietary interest) together with one or more joint inventors, then the joint inventor or inventors who are also the applicant should be
`identified in this section.
`
`I Remove I
`
`lo Legal Representative under 35 U.S.C. 117
`® Assignee
`lo
`0 Person to whom the inventor is obligated to assign.
`If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:
`
`Person who shows sufficient proprietary interest
`
`I Clear I
`lo Joint Inventor
`
`Name of the Deceased or Legally Incapacitated Inventor :I
`If the Applicant is an Organization check here.
`~
`
`Organization Name
`
`I Vanda Pharmaceuticals, Inc.
`
`Mailing Address Information:
`
`Address 1
`
`Address 2
`
`City
`Country i I us
`
`Phone Number
`
`EFS Web 2.2.6
`
`2200 Pennsylvania Avenue
`
`Washington
`
`I
`
`I
`
`State/Province
`
`DC
`
`Postal Code
`
`20037
`
`Fax Number
`
`Roxane Labs., Inc.
`Exhibit 1002
`Page 009
`
`

`
`PTO/AIN14 (03-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`VAND-0002-US-CON2
`
`Application Number
`
`Title of Invention METHODS FOR THE ADMINISTRATION OF ILOPERIDONE
`
`Email Address
`
`Additional Applicant Data may be generated within this form by selecting the Add button.
`
`Add
`
`Non-Applicant Assignee Information:
`
`Providing assignment information in this section does not subsitute for compliance with any requirement of part 3 of Title 37 of CFR to
`have an assignment recorded by the Office.
`
`Assignee 1
`
`Complete this section only if non-applicant assignee information is desired to be included on the patent application publication in
`accordance with 37 CFR 1.215(b). Do not include in this section an applicant under 37 CFR 1.46 (assignee. person to whom the
`inventor is obligated to assign, or person who otherwise shows sufficient proprietary interest), as the patent application publication will
`include the name of the applicant(s).
`
`If the Assignee is an Organization check here.
`
`Prefix
`
`Given Name
`
`D
`Middle Name
`
`Family Name
`
`Suffix
`
`I Remove I
`
`Mailing Address Information:
`
`Address 1
`
`Address 2
`
`City
`Country i
`
`I
`Phone Number
`
`Email Address
`
`I
`
`State/Province
`
`Postal Code
`
`Fax Number
`
`Additional Assignee Data may be generated within this form by selecting the Add button.
`
`I Add
`
`I
`
`Signature·
`NOTE: This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4 for signature requirements and
`certifications
`
`I Remove I
`
`Signature
`
`/Jayme M. Torelli/
`
`Date (YYYY-MM-DD) 2014-01-08
`
`First Name
`
`Jayme
`
`I Last Name I Torelli
`
`Additional Signature may be generated within this form by selecting the Add button.
`
`62735
`Registration Number
`I Add
`I
`
`EFS Web 2.2.6
`
`Roxane Labs., Inc.
`Exhibit 1002
`Page 010
`
`

`
`PTO/AIN14 (03-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`VAND-0002-US-CON2
`
`Application Number
`
`Title of Invention METHODS FOR THE ADMINISTRATION OF ILOPERIDONE
`
`This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which
`is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This
`collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data
`sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of lime you require to
`complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and
`Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR
`COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
`
`EFS Web 2.2.6
`
`Roxane Labs., Inc.
`Exhibit 1002
`Page 011
`
`

`
`Privacy Act Statement
`
`The Privacy Act of 1974 (P .L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to
`a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection
`of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is volu